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Introduction {#s1}
============

Assessment of both the independent effect of critical gene variations and their joint effect with environmental factors is of great significance to reveal the architecture of gastric cancer predisposition and improve personalized prevention for individuals at risk [@pone.0115955-Roukos1]. Pepsinogen C (PGC or PGII), one of the most important members of aspartic proteinase family, is the precursor of pepsin C that functions as a key digestive enzyme in stomach [@pone.0115955-Gritti1]. Human PGC starts to appear in stomach since the late phase of embryonic development, indicating its involvement in the terminal differentiation of gastric mucosa [@pone.0115955-Yasugi1]. The PGC expression in stomach plays an important role in sustaining normal morphology and physiological function of epithelial cells [@pone.0115955-Massarrat1]. Our research group previously found that histological PGC protein expression gradually declined with the cellular malignant transformation from the originally normal state to inflammation, precancerous conditions and finally to carcinoma. Additionally, several previous studies in extragastric tissues reported that low-expression of PGC protein was closely related to poor differentiation and unflavored survival in patients with breast, prostate, ovarian, or pancreatic cancers [@pone.0115955-Scorilas1]--[@pone.0115955-Truan1]. These evidences exhibited that PGC has a general role in suppressing the tumor development.

PGC gene is located at chromosome 6p21.3--21.1, encompassing 9 exons and 8 introns (<http://www.ncbi.nlm.nih.gov/gene/>). So far, twelve common single nucleotide polymorphisms (SNP) have been identified within PGC gene and its extended 5000 bp upstream and downstream sequences by the HapMap project in Chinese Han Beijing population (Release 27,Phase I+II+III, [S1 Fig](#pone.0115955.s001){ref-type="supplementary-material"}.). Among these twelve SNPs, eight tagging SNPs (tagSNPs) were picked up to efficiently assess the role of PGC polymorphisms in gastric carcinogenesis ([S1 Table](#pone.0115955.s003){ref-type="supplementary-material"}). We previously identified the associations of three tagSNPs (rs4711690, rs9471643 and rs6458238 polymorphisms) in PGC gene with risk of atrophic gastritis or gastric cancer [@pone.0115955-He1]. However, the roles of the other five tagSNPs (rs6941539, rs6912200, rs3789210, rs6939861 and rs2040017) of PGC gene in susceptibility to gastric cancer remain unknown, which requires further clarification.

Apart from genetic factors, environmental factors are also considered very important in the initiation and progression of gastric cancer, among which H. pylori is thought to be the strongest risk [@pone.0115955-Fock1]. Moreover, PGC protein has been well-known as a good indicator and effector for *H. pylori* infection and *H. pylori*-related gastropathologies [@pone.0115955-DiMario1]--[@pone.0115955-He2]. For instance, the expression level of serum PGC protein promptly increased when the individual was infected by *H. pylori* while gradually declined and recovered to the baseline level once this microbe was eradicated [@pone.0115955-DiMario1]. Hence, in addition to the PGC genetic variations, the interaction of PGC tagSNP with *H. pylori* infection is also a key component of gastric cancer susceptibility that should not be overlooked.

To comprehensively investigate the role of PGC genetic polymorphisms in altering the susceptibility to gastric cancer, we examined the individual effect of PGC tagSNP and its interaction with *H. pylori* infection on the risks of gastric cancer and its precursor, atrophic gastritis; and then preliminarily explored the influence of PGC tagSNP on its gene expression at both transcriptional and translational levels.

Materials and Methods {#s2}
=====================

Sample collection {#s2a}
-----------------

This study was approved by the human ethics review committee of China Medical University. Written informed consent was obtained from each participant. The subjects enrolled in this research came from the same study population as in our previous study [@pone.0115955-He1]. A full description of the inclusion criteria, diagnosis criteria and characteristics of the study population has been previously described [@pone.0115955-He1]. Briefly, all the included subjects were Chinese residing in northern China, and were recruited from a health check program for gastric cancer screening or from hospitals in Zhuanghe and Shenyang of Liaoning Province, China, between 2002 and 2011. The healthy subjects in the present study comprised individuals with normal stomaches and subjects with only slight or moderate superficial gastritis without atrophic or intestinal metaplasia lesions. Subjects who had a history of other malignancies were excluded. For the genetic association study, a total of 2311 subjects consisting of 642 gastric cancer, 774 atrophic gastritis and 895 healthy control subjects were included. For the PGC mRNA study, 38 patients with gastric cancer were enrolled for the analysis of *PGC* mRNA, from whom cancerous gastric tissues and corresponding noncancerous tissues that were at least 5 cm away from the tumor edge were collected under gastrectomy at the First Affiliated Hospital of China Medical University between 2009 and 2011. For the histological PGC protein study, 226 healthy subjects were randomly selected from the health check program for gastric cancer screening in Zhuanghe performed in 2002, 2008 and 2009. These healthy subjects were endoscopically and histologically identified to have normal mucosa or only slight superficial gastritis without evidence of gastrointestinal symptoms. Biopsy specimens were obtained under gastroscopy from gastric body, angulus and antrum of each subject for the detection of PGC protein *in situ*. For the serum PGC protein study, all the study samples with available serum were included, and finally a total of 1850 subjects consisting of 832 healthy subjects, 737 atrophic gastritis and 281 gastric cancer cases were analyzed.

Genotyping of *PGC* tagSNPs {#s2b}
---------------------------

Genomic DNA was isolated from peripheral blood lymphocytes by the routine phenol--chloroform method as previously described [@pone.0115955-He1]. Each DNA sample was diluted to a working concentration of 50 ng/µl for genotyping. Assay design and SNP genotyping were performed by Biomiao (Beijing, China) using the Sequenom MassARRAY platform (Sequenom, San Diego, CA, USA) according to the manufacturer\'s instructions. All samples were randomized on 384-well plates and blinded for disease status. Fifty randomly selected samples were repeatedly genotyped, and the results were 100% concordant.

Quantitative detection of *PGC* mRNA {#s2c}
------------------------------------

The detailed method for the measurement of *PGC* mRNA is described in our previous study [@pone.0115955-He1]. In brief, total RNA from approximately 50 mg cancerous or noncancerous specimens was isolated using TRIzol reagent (Life Technologies, Carlsbad, CA, USA). About 1.5 µg total RNA was converted into complementary DNA using a Quantscript RT kit (Tiangen Biotech, Beijing, China). The mRNA levels for *PGC* and an internal-control gene, glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*), were examined using SYBR Premix Ex Taq II (TaKaRa Biotech, Dalian, China) in an Eppendorf Mastercycler Gradient System (Eppendorf AG, Hamburg, Germany) according to the manufacturer\'s protocol. Melting curve analysis was performed to exclude the presence of nonspecific products and primer-dimers. No-template controls were included in each experiment. The relative quantification of mRNA levels was calculated using the 2^−ΔΔCt^ method [@pone.0115955-Livak1].

Immunohistochemistry (IHC) and semi-quantitative assessment of PGC protein *in situ* {#s2d}
------------------------------------------------------------------------------------

For the retrieval of antigens, 5 µm thick sections were cut from formalin-fixed, paraffin-embedded tissue samples. Sections were dewaxed by heating in citrate buffer (pH 6.0) for 10 min using a microwave. Overnight incubation at 4°C was carried out for the binding of primary antibody (PGII, anti-pepsinogen C antibody, trade name: 2D5, 1∶400 dilution; this antibody was donated by the Japan Clinical Inspection Institute) [@pone.0115955-Konishi1], [@pone.0115955-Ning1]. Streptavidin-peroxidase two-step immunostaining was then performed according to kit instructions (Kit-9801D2, Maixin Company, Fujian, China). A more detailed method for detecting PGC protein *in situ* has been described previously [@pone.0115955-Li1].

Image-Pro Plus software (version 6.0, Media Cybernetics, Silver Spring, MD, USA) was used to quantify the IHC staining of PGC protein. The level of PGC protein was calculated based on the product of the average staining intensity from various images, minimizing possible variation in the staining detection. Using identical microscope and camera settings, four digital images of different fields (400× objective lens) from each sample were taken to accurately reflect the overall staining. To count the exact area of specific PGC staining in each image, the discrimination plane was set at 0--100 in the H channel, 0--255 in the S channel, and 0--200 in I channel. Other nonspecific areas were masked using the setting of 255, 0, 0. To measure the optical density, the original color image was converted to a gray scale image ([S2 Fig](#pone.0115955.s002){ref-type="supplementary-material"}.). The integrated optical density (IOD) of all the positive PGC staining in each gray scale image and the area of interest (AOI) of PGC staining was measured. The mean density (IOD/AOI) represented the concentration of specific PGC protein in each image. The mean density of four digital images from different fields was finally calculated to represent the average value of PGC protein in each sample.

ELISA assessment of *H. pylori*-Immunoglobin (Ig) G and PGC protein in serum {#s2e}
----------------------------------------------------------------------------

Serum *H. pylori*-IgG and PGC protein concentrations were determined as described previously [@pone.0115955-He2] by ELISA (Eenzyme-linked immunoabsorbent assay) (*H. pylori*--IgG ELISA kit and PGII ELISA kit, BIOHIT, Helsinki, Finland) respectively. A reading \>34 enzyme immune-units was assumed to be *H. pylori* seropositive.

Statistical analysis {#s2f}
--------------------

The Hardy-Weinberg Equilibrium (HWE) of the genotype distribution of each SNP was detected by chi-square test in the control group. The odds ratio (OR) and corresponding 95% interval confidence (CI) were calculated to measure the strength of association between genotype and the risks of gastric cancer and atrophic gastritis. The genetic effect of a single tagSNP on disease risk was detected by multivariate regression analysis controlling for the sex, age and status of *H. pylori* infection. For the haplotype analysis of the four PGC tagSNPs (rs6941539-rs6912200-rs3789210-rs6939861), we set the other haplotypes pooled together as a reference, and assessed the genetic effect of each haplotype with a frequency of at least more than 0.03 in healthy controls, which also controlled for the sex, age and status of *H. pylori* infection. And likelihood ratio tests were performed to assess the interaction effect between genotype and *H. pylori* by comparing the model that only involved the main effects with the full model that also contained the interaction term. To evaluate the association between genotype and gene expression, the distribution of each variable was first tested by the Kolmogorov-Smirnov test. Accordingly, for PGC mRNA data and PGC protein in serum which deviated from a normal distribution, their medians were compared between two groups using Mann-Whitney U test; while for the PGC protein data which fitted a normal distribution, their means were compared using Student\'s t test. Additionally, the correlation between genotypes and PGC protein in serum were evaluated using partial correlation controlling for sex, age and status of *H. pylori* infection.

All the analyses mentioned above were performed using SPSS 13.0 software (SPSS, Chicago, IL, USA) except for that the haplotype analysis was performed under UNPHASED version 3.1.5 software [@pone.0115955-Dudbridge1]. All P values were two sided, and P values \<0.05 were considered statistically significant.

Results {#s3}
=======

Individual effect of a single PGC tagSNP on the risks of gastric cancer and atrophic gastritis {#s3a}
----------------------------------------------------------------------------------------------

Because of the confliction of primers in multiplex PCR, rs2040017 polymorphism could not be detected according to the original design, and four PGC tagSNPs, rs6941539, rs6912200, rs3789210 and rs6939861, were successfully genotyped and analyzed in this study. We first assessed the individual analysis of each polymorphism ([Table 1](#pone-0115955-t001){ref-type="table"}). As a result, the AG, AA and AG/AA genotypes of rs6939861 were associated with increased risks of both gastric cancer and atrophic gastritis compared with the common GG genotype (all P\<0.05). In addition, rs3789210 CG/GG genotypes were marginally associated with reduced risk of atrophic gastritis compared with the common CC genotype (P = 0.048). We did not observe statistical association between rs6912200 and rs6914539 genotypes and disease risk (all P\>0.05).

10.1371/journal.pone.0115955.t001

###### Association between a single PGC tagSNP and risks of atrophic gastritis and gastric cancer.

![](pone.0115955.t001){#pone-0115955-t001-1}

  PGC tagSNP     CON(%)       GA(%)       GC(%)         GA vs. CON        GC vs. CON                        
  ------------ ----------- ----------- ----------- --------------------- ------------ --------------------- -----------
  rs3789210                                                                                                 
  CC            674(75.3)   612(79.1)   487(75.9)            1                                  1           
  CG            202(22.6)   148(19.1)   143(22.3)     0.80(0.62,1.03)       0.084        1.00(0.77,1.30)       0.983
  GG             19(2.1)     14(1.8)     12(1.9)      0.63(0.31,1.31)       0.217        0.64(0.29,1.40)       0.262
  CG/GG                                             **0.78(0.61,1.00)**   **0.048**      0.96(0.74,1.24)       0.750
  rs6912200                                                                                                 
  CC            227(25.4)   198(25.7)   166(26.0)            1                                  1           
  CT            448(50.2)   385(50.0)   318(49.8)     1.06(0.82,1.35)       0.673        0.92(0.70,1.20)       0.519
  TT            217(24.3)   187(24.3)   155(24.3)     1.07(0.80,1.44)       0.661        0.96(0.71,1.30)       0.796
  CT/TT                                               1.06(0.84,1.34)       0.637        0.93(0.72,1.19)       0.547
  rs6939861                                                                                                 
  GG            390(45.8)   298(39.7)   246(39.6)            1                                  1           
  AG            396(46.5)   373(49.7)   313(50.4)   **1.25(1.01,1.56)**   **0.045**    **1.29(1.02,1.62)**   **0.034**
  AA             65(7.6)    79(10.5)    62(10.0)    **1.62(1.11,2.37)**   **0.013**    **1.53(1.01,2.31)**   **0.044**
  AG/AA                                             **1.30(1.06,1.61)**   **0.014**    **1.32(1.05,1.65)**   **0.015**
  rs6941539                                                                                                 
  CC            641(72.1)   531(69.1)   460(71.8)            1                                  1           
  CT            227(25.5)   221(28.7)   164(25.6)     1.17(0.93,1.47)       0.187        1.04(0.81,1.34)       0.739
  TT             21(2.4)     17(2.2)     17(2.7)      0.96(0.48,1.91)       0.911        1.17(0.59,2.35)       0.655
  CT/TT                                               1.15(0.92,1.44)       0.221        1.05(0.83,1.35)       0.672

All tests were adjusted by age, sex and status of *H. pylori* infection. The results highlighted in bold show associations with disease risk (P values \<0.05). Abbreviation: CON: healthy controls; GA: atrophic gastritis, GC: gastric cancer.

Joint effect of multiple PGC tagSNPs on the risks of gastric cancer and atrophic gastritis {#s3b}
------------------------------------------------------------------------------------------

Next, we assessed the effect of common haplotypes of PGC rs6941539-rs6912200-rs3789210-rs6939861 loci on disease risk. Seven haplotypes with frequencies of at least more than 0.03 in control group were observed and analyzed ([Table 2](#pone-0115955-t002){ref-type="table"}). With the other haplotypes pooled together as a reference, we found that both TTCA and CTCA haplotypes were associated with an increased atrophic gastritis risk (P = 0.001 and 0.041, respectively) while TTGG haplotype was related with a reduced atrophic gastritis risk (P = 0.023). For gastric cancer, the TTCA haplotype was associated with an increased gastric cancer risk (P = 0.021) and the TTGG haplotype was associated with a reduced gastric cancer risk (P = 0.017).

10.1371/journal.pone.0115955.t002

###### Association between haplotypes of PGC tagSNPs and risks of atrophic gastritis and gastric cancer.

![](pone.0115955.t002){#pone-0115955-t002-2}

  Haplotype[b](#nt103){ref-type="table-fn"}        CON           GA            GC            GA vs. CON                        GC vs. CON       
  ------------------------------------------- ------------- ------------- ------------- --------------------- ----------- --------------------- -----------
  TTCA                                          70(4.18%)    100(6.76%)     74(6.00%)    **1.78(1.20,2.65)**   **0.001**   **1.70(1.11,2.60)**   **0.021**
  TTCG                                         467(27.84%)   364(24.62%)   326(26.63%)     0.86(0.72,1.03)       0.112       0.96(0.80,1.16)       0.670
  TTGG                                          65(3.90%)     45(3.05%)     27(2.19%)    **0.59(0.37,0.94)**   **0.023**   **0.54(0.31,0.94)**   **0.017**
  TCCA                                         166(9.88%)    155(10.47%)   126(10.27%)     1.32(1.00,1.73)       0.053       1.17(0.87,1.57)       0.277
  TCCG                                         516(30.73%)   465(31.39%)   366(29.87%)     1.02(0.86,1.21)       0.851       0.92(0.75,1.10)       0.422
  TCGA                                         134(8.01%)    106(7.17%)    101(8.23%)      0.83(0.62,1.12)       0.246       1.00(0.74,1.35)       0.896
  CTCA                                         133(7.90%)    155(10.47%)   111(9.06%)    **1.33(1.01,1.74)**   **0.041**     1.19(0.88,1.61)       0.837
  CTCG                                         105(6.24%)     74(5.03%)     71(5.78%)      0.78(0.54,1.12)       0.178       0.90(0.62,1.30)       0.216

, P, OR and corresponding 95%CI for individual haplotype test compares with the remaining haplotype pooled together;

, haplotype of Haplotype of rs6941539 C\>T-rs6912200 C\>T-rs3789210 C\>G-rs6939861 G\>A. All tests were adjusted by age, sex and status of H. pylori infection. The results highlighted in bold show associations with disease risk (P values \<0.05). Abbreviation: CON: healthy controls; GA: atrophic gastritis, GC: gastric cancer.

Interaction effect between PGC tagSNP and *H. pylori* on the risks of gastric cancer and atrophic gastritis {#s3c}
-----------------------------------------------------------------------------------------------------------

We further performed both stratification analysis and interaction analysis to investigate whether the genetic effect of PGC tagSNP on disease risk was modified by the status of *H. pylori* infection. In the stratified analysis according to *H. pylori* infection, rs3789210 CG and CG/GG genotypes showed statistical associations with a reduced atrophic gastritis risk in the subjects without *H. pylori* infection (P = 0.020 and 0.021 respectively); and rs6939861 AA and AG/AA genotypes were associated with an increased risk of gastric cancer (P = 0.042 and 0.034 respectively)([Table 3](#pone-0115955-t003){ref-type="table"}). We next used Breslow-Day test to compare the difference in the odds ratios between *H. pylori* negative and positive subgroups. Consequently, rs6912200 CT, TT and CT/TT genotypes exhibited statistically different effects on gastric cancer risk between the two subgroups (P = 0.038, 0.025 and 0.017, respectively), suggesting that *H. pylori* had a modifying effect on rs6912200 genotypes ([Table 3](#pone-0115955-t003){ref-type="table"}). Subsequently, interaction analysis confirmed that rs6912200 CT/TT genotypes had a positive interaction with *H. pylori* infection with an interacted OR of 1.75 (P = 0.030), suggesting a synergistic risk effect of rs6912200 CT/TT genotypes and *H. pylori* infection on gastric cancer development ([Table 4](#pone-0115955-t004){ref-type="table"}). The individuals with CT/TT genotype and *H. pylori* infection demonstrated a substantially increased risk of gastric cancer compared with the subjects with CC genotype but without *H. pylori* infection (OR = 2.48, 95%CI:1.77,3.48) ([Table 4](#pone-0115955-t004){ref-type="table"}).

10.1371/journal.pone.0115955.t003

###### Stratification analysis of PGC tagSNP with atrophic gastritis and gastric cancer risks according to the status of *H. pylori* infection.
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  PGC tagSNP    No. of Con/GA/GC   GA vs. CON                          GC vs. CON                                                                                             
  ------------ ------------------ ------------- --------------------- ------------ ------------------ ------- ------- ----------------- ----------- ----------------- ------- -----------
  rs3789210                                                                                                                                                                   
  CC              481/253/236      193/359/251            1                                1                                  1                             1                 
  CG               149/52/71        53/96/72     **0.66(0.46,0.94)**   **0.020**    1.03(0.70,1.51)    0.899   0.144   0.97(0.69,1.35)     0.850     1.04(0.68,1.59)   0.856     0.782
  GG                 9/4/6           10/10/6       0.82(0.25,2.71)       0.750      0.58(0.23,1.42)    0.231   0.550   1.12(0.38,3.36)     0.834     0.39(0.13,1.16)   0.089     0.144
  CG/GG                                            0.67(0.48,0.94)     **0.021**    0.95(0.66,1.37)    0.781   0.242   0.98(0.71,1.35)     0.885     0.93(0.62,1.39)   0.722     0.866
  rs6912200                                                                                                                                                                   
  CC               154/72/91        73/126/74             1                                1                                  1                             1                 
  CT              319/164/146      129/221/172     1.10(0.79,1.54)       0.582      1.01(0.70,1.46)    0.958   0.684   0.76(0.54,1.06)     0.106     1.23(0.81,1.87)   0.336   **0.038**
  TT               164/71/74        53/116/81      0.92(0.62,1.370       0.680      1.31(0.84,2.05)    0.229   0.294   0.73(0.49,1.070     0.104     1.56(0.94,2.58)   0.084   **0.025**
  CT/TT                                            1.04(0.75,1.430       0.825      1.09(0.78,1.54)    0.611   0.899   0.74(0.54,1.02)     0.066     1.31(0.88,1.95)   0.186   **0.017**
  rs6939861                                                                                                                                                                   
  GG              274/116/113      116/182/133            1                                1                                  1                             1                 
  AG              286/150/162      110/223/151     1.23(0.92,1.66)       0.163      1.29(0.93,1.79)    0.134   0.851   1.32(0.98,1.78)     0.073     1.24(0.85,1.79)   0.264     0.555
  AA                46/32/32        19/47/30       1.64(1.00,2.71)       0.052      1.58(0.88,2.84)    0.128   0.916   1.72(1.02,2.90)   **0.042**   1.28(0.66,2.49)   0.457     0.620
  AG/AA                                            1.29(0.97,1.71)       0.078      1.33(0.97,1.820)   0.082   0.890   1.37(1.02,1.84)   **0.034**   1.24(0.87,1.77)   0.238     0.513
  rs6941539                                                                                                                                                                   
  CC              459/210/221      182/321/239            1                                1                                  1                             1                 
  CT               160/90/83        67/131/81      1.23(0.90,1.670       0.190      1.08(0.76,1.530    0.675   0.660   1.13(0.82,1.56)     0.465     0.92(0.62,1.38)   0.697     0.527
  TT                 16/6/9          5/11/8        0.78(0.30,2.02)       0.604      1.25(0.43,3.69)    0.683   0.565   1.12(0.47,2.64)     0.798     1.28(0.39,4.23)   0.690     0.953
  CT/TT                                            1.19(0.88,1.60)       0.263      1.09(0.77,1.53)    0.623   0.780   1.13(0.83,1.54)     0.452     0.95(0.64,1.40)   0.782     0.554

, tests were adjusted by sex and age;

, P value for BreslowDay test comparing the difference of OR of *H. pylori* negative subgroup with OR of *H. pylori* positive subgroup. The results highlighted in bold show associations with disease risk (P values \<0.05). Abbreviation: CON: healthy controls; GA: atrophic gastritis, GC: gastric cancer.

10.1371/journal.pone.0115955.t004

###### Interaction effect of PGC tagSNP and *H. pylori* on risks of atrophic gastritis and gastric cancer.

![](pone.0115955.t004){#pone-0115955-t004-4}

  PGC tagSNP                                         GA vs. CON                                GC vs. CON                                    
  ------------ ----------------------- --------------------------------------- ------------------------------------------- ----------------- -----------------
  rs3789210                                                                                                                                  
  CG/GG         No. of controls/cases                  158/56                                    63/106                         158/77             63/78
                      OR(95%CI)                        1(ref)                                5.10(3.28,7.93)                    1(ref)        2.83(1.80,4.43)
  CC            No. of controls/cases                  481/253                                   193/359                        481/236           193/251
                      OR(95%CI)                    1.50(1.07,2.12)                           5.44(3.82,7.76)                1.02(0.74,1.42)   3.02(2.13,4.28)
                                        P for interaction  = 0.177, OR = 0.71     P for interaction  = 0.871, OR = 1.04                      
  rs6912200                                                                                                                                  
  CC            No. of controls/cases                  154/72                                    73/126                         154/92             73/74
                      OR(95%CI)                        1(ref)                                3.75(2.50,5.62)                    1(ref)        1.91(1.24,2.95)
  CT/TT         No. of controls/cases                  483/235                                   182/337                        483/220           182/253
                      OR(95%CI)                    1.03(0.75,1.430                           4.08(2.92,5.71)                0.74(0.54,1.02)   2.48(1.77,3.48)
                                        P for interaction  = 0.826, OR = 1.05   **P for interaction  = 0.030, OR = 1.75**                    
  rs6939861                                                                                                                                  
  GG            No. of controls/cases                  274/116                                   116/182                        274/113           116/133
                      OR(95%CI)                        1(ref)                                3.82(2.77,5.26)                    1(ref)        3.00(2.12,4.25)
  AG/AA         No. of controls/cases                  332/182                                   129/270                        332/194           129/181
                      OR(95%CI)                    1.28(0.97,1.70)                           5.08(3.75,6.90)                1.38(1.03,1.85)   3.73(2.68,5.18)
                                        P for interaction  = 0.854, OR = 1.04     P for interaction  = 0.660, OR = 0.90                      
  rs6941539                                                                                                                                  
  CC            No. of controls/cases                  459/210                                   182/321                        459/221           182/239
                      OR(95%CI)                        1(ref)                                4.00(3.12,5.12)                    1(ref)        3.06(2.35,3.99)
  CT/TT         No. of controls/cases                  176/96                                    72/142                         176/92             72/89
                      OR(95%CI)                    1.19(0.88,1.60)                           4.41(3.18,6.14)                1.13(0.83,1.54)   2.91(2.01,4.21)
                                        P for interaction  = 0.735, OR = 0.93     P for interaction  = 0.496, OR = 0.84                      

The Interaction effect were assessed by the likelihood ratio test, comparing the fit of the logistic model that included the main effects of sex, age, *H. pylori* and PGC genotype with a fully parameterized model containing the multiplicative interaction terms of genotype and *H. pylori*. The results highlighted in bold show associations with disease risk (P values \<0.05). Abbreviation: CON: healthy controls; GA: atrophic gastritis, GC: gastric cancer.

Correlation between PGC tagSNP and PGC expression at both mRMA and protein levels {#s3d}
---------------------------------------------------------------------------------

We preliminarily explored the influence of PGC tagSNP on gene expression at mRNA and protein levels. We first examined PGC mRNA in 38 pairs of cancerous tissues and matched non-cancerous tissues at least 5 cm apart from the edge of tumorous lesions. However, we did not observe any statistical correlation between the four PGC tagSNPs and PGC mRNA expression level in these samples (all P\>0.05, [table 5](#pone-0115955-t005){ref-type="table"}).

10.1371/journal.pone.0115955.t005

###### Correlation between PGC tagSNP and levels of PGC mRNA expression.
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               N    Non-cancerous tissue          N           Cancerous tissue                                              
  ----------- ---- ---------------------- ------------------ ------------------ ---- ------------------- ------------------ -------
  rs3789210                                                                                                                 
  CC           33    0.44(−1.50, 2.12)     0.74(0.23, 2.90)                      33   0.81(−0.40, 3.78)   0.57(0.07, 1.32)  
  CG           5     −1.11(−1.85, 4.74)    2.16(0.42, 3.69)        0.675         5    2.62(0.32, 7.52)    0.16(0.07, 0.98)   0.353
  rs6912200                                                                                                                 
  CC           9     0.65(−0.94, 2.96)     0.64(0.15, 1.92)                      9    0.10(−0.86, 5.01)   0.93(0.03, 1.85)  
  CT           21    −0.66(−2.14, 3.45)    1.58(0.09, 4.52)        0.563         21   1.04(−0.45, 3.33)   0.49(0.10, 1.37)   0.965
  TT           8     0.35(−1.61, 1.46)     0.79(0.37, 3.56)        0.541         8    1.93(0.31, 3.67)    0.29(0.08, 0.81)   0.673
  CT/TT        29    0.00(−1.98, 2.06)     1.00(0.24, 3.97)        0.499         29   1.14(−0.25, 3.33)   0.45(0.10, 1.03)   0.840
  rs6939861                                                                                                                 
  GG           19    0.65(−2.46, 3.59)     0.64(0.08, 5.50)                      19   0.52(−1.18, 3.54)   0.70(0.09, 2.27)  
  AG           15    −0.66(−1.57, 1.56)    1.58(0.34, 2.97)        0.451         15   2.62(0.10, 4.34)    0.16(0.05, 0.93)   0.190
  AA           4     1.10(−0.52, 3.36)     0.52(0.12, 1.53)        0.667         4    0.71(0.49, 1.88)    0.62(0.30, 0.71)   0.725
  AG/AA        19    −0.24(−1.11, 1.75)    1.18(0.30, 2.16)        0.644         19   1.26(0.45, 4.01)    0.42(0.06, 0.73)   0.212
  rs6941539                                                                                                                 
  CC           24    0.13(−2.06, 1.70)     0.92(0.31, 4.19)                      24   1.25(−0.53, 3.58)   0.42(0.08, 1.46)  
  CT           13    0.65(−1.37, 3.70)     0.64(0.08, 2.62)        0.337         13   0.69(−0.40, 3.53)   0.62(0.22, 1.32)   0.561
  TT           1           −0.98                 1.97              0.720         1          5.68                0.20         0.240
  CT/TT        14    0.65(−1.28, 3.64)     0.64(0.08, 2.44)        0.427         14   0.75(−0.33, 5.71)   0.60(0.02, 1.26)   0.800

All tests were used Mann-Whitney U test.

We further investigated the influence of genotypes on PGC protein levels. Serum PGC protein levels were detected by ELISA in a total of 1850 subjects consisting of 832 controls, 737 atrophic gastritis and 281 gastric cancer patients ([table 6](#pone-0115955-t006){ref-type="table"}). Considering normal mucosa and/or mild superficial gastritis as an ascertained benign condition that was minimally affected by other confounding factors, 226 healthy subjects offering a total of 284 specimens were analyzed for histological PGC protein. To further eliminate the confounding effect of particular locations on gastric tissues, we divided the tissue specimens into three subgroups according to their locations: 75 gastric body, 72 gastric angulus and 137 gastric antrum specimens ([table 7](#pone-0115955-t007){ref-type="table"}). The overall analysis of PGC protein found no statistical correlation between PGC tagSNP and PGC protein expression either in the 284 tissue specimens detected by immunohistochemistry or in the 1850 serum samples detected by ELISA. In the subgroup analysis of histological PGC protein in immunohistochemistry experiment, we observed that the subjects who carried rs6912200 CT, TT and CT/TT genotypes had lower histological levels of PGC protein in gastric body specimens (P = 0.014, 0.032 and 0.042, respectively). Similarly, in the subgroup analysis of serum PGC protein in ELISA experiment, we found correlations between PGC rs6912200 variant genotype and decreased expression levels of PGC protein in controls subjects (P = 0.026). Moreover, PGC rs6941539 CT and CT/TT genotypes had decreased expression levels of PGC protein in gastric cancer patients (P = 0.007 and 0.014, respectively).

10.1371/journal.pone.0115955.t006

###### Correlation between PGC tagSNP and levels of PGC protein expression in serum.
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  SNP          Total    Healthy subject    Atrophic gastritis   Gastric cancer                                                                                                                                   
  ----------- ------- ------------------- -------------------- ---------------- ----- ------------------ ------- ----------- ----- ------------------- ----------- ------- ----- ------------------- ----------- -------
  rs3789210                                                         0.883                                           0.853                                           0.507                                         0.627
  CC           1421    9.30(6.00,16.50)                                          629   7.70(5.30,11.88)                       584   11.70(6.87,19.30)                       208   12.65(7.01,21.84)              
  CG            391    9.20(6.00,17.00)          0.871                           185   7.49(5.10,10.15)   0.364               141   12.40(6.97,20.50)     0.564             65    16.00(8.35,24.29)     0.119    
  GG            38     9.70(6.55,17.00)          0.741                           18    8.85(5.95,16.48)   0.212               12    12.10(6.20,17.05)     0.439              8    11.98(7.05,23.15)     0.890    
  CG/GG         429    9.20(6.07,17.00)          0.727                           203   7.50(5.10,10.50)   0.596               153   12.40(6.80,19.40)     0.723             73    14.98(8.17,24.29)     0.159    
  rs6912200                                                         0.300                                         **0.026**                                         0.603                                         0.582
  CC            470    10.05(6.10,16.72)                                         218   8.10(5.38,12.37)                       188   12.45(7.51,19.90)                       64    10.28(7.33,23.90)              
  CT            931    9.20(5.80,16.70)          0.177                           416   7.68(5.30,11.70)   0.467               368   11.40(6.20,18.88)   **0.039**           147   14.50(7.04,23.27)     0.271    
  TT            449    9.00(6.20,16.35)          0.248                           198   7.25(5.09,9.77)    0.055               181   11.80(7.75,19.85)     0.512             70    13.50(7.23,22.07)     0.420    
  CT/TT        1380    9.10(5.90,16.68)          0.153                           614   7.50(5.20,10.73)   0.196               549   11.60(6.60,19.20)     0.083             217   14.20(7.07,22.95)     0.271    
  rs6939861                                                         0.296                                           0.278                                           0.268                                         0.829
  GG            795    9.00(5.90,16.90)                                          384   7.50(5.32,11.70)                       297   12.80(6.95,18.50)                       114   14.30(6.38,23.07)              
  AG            888    9.30(6.03,16.28)          0.979                           383   7.70(5.20,11.70)   0.938               361   11.00(6.60,18.50)     0.167             144   13.33(7.63,23.58)     0.784    
  AA            167    10.46(6.70,16.30)         0.334                           65    8.07(5.60,11.30)   0.839               79    13.06(8.10,19.30)     0.736             23    12.30(7.04,23.30)     0.829    
  AG/AA        1055    9.40(6.10,16.30)          0.800                           448   7.80(5.20,11.68)   0.990               440   11.45(6.70,18.50)     0.280             167   13.20(7.60,23.30)     0.851    
  rs6941539                                                         0.302                                           0.369                                           0.786                                         0.304
  CC           1327    9.30(6.20,16.74)                                          604   7.70(5.40,11.60)                       514   11.85(6.90,19.30)                       209   14.40(7.75,23.55)              
  CT            481    9.20(5.70,15.89)          0.147                           208   7.88(5.20,11.88)   0.828               207   11.40(6.50,18.36)     0.541             66    9.12(5.41,19.18)    **0.007**  
  TT            42     10.35(5.58,18.68)         0.929                           20    6.00(4.95,10.45)   0.253               16    18.35(8.47,23.64)     0.243              6    17.80(8.95,29.50)     0.687    
  CT/TT         523    9.20(5.70,15.90)          0.163                           228   7.79(5.19,11.70)   0.618               223   11.70(6.70,19.40)     0.751             72    10.10(5.53,21.67)   **0.014**  

, P values for Mann-Whitney Test comparing the difference of variables between two groups;

, P values for partial correlation analysis controlling for sex, age and status of H. pylori infection. The results highlighted in bold show associations with expression levels of PGC protein in serum (P values \<0.05).

10.1371/journal.pone.0115955.t007

###### Correlation between PGC tagSNP and levels of PGC protein expression in situ.
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  PGC tagSNP    Total (N = 284)   Gastric corpus (N = 75)   Gastric angulus (N = 72)   Gastric antrum (N = 137)                                                                           
  ------------ ----------------- ------------------------- -------------------------- -------------------------- ------------- ----------- ---- ------------- ------- ----- ------------- -------
  rs3789210                                                                                                                                                                               
  CC                  228               0.194±0.048                                               58              0.226±0.046               63   0.192±0.044           107   0.177±0.044  
  CG                  47                0.192±0.053                  0.841                        14              0.244±0.055     0.196     7    0.172±0.021   0.225   26    0.169±0.037   0.420
  GG                   9                0.210±0.050                  0.320                        3               0.265±0.041     0.149     2    0.181±0.024   0.704    4    0.183±0.029   0.771
  CG/GG               56                0.195±0.053                  0.860                        17              0.248±0.052     0.093     9    0.017±0.021   0.214   30    0.171±0.036   0.517
  rs6912200                                                                                                                                                                               
  CC                  68                0.198±0.158                                               17              0.260±0.067               18   0.188±0.033           33    0.172±0.036  
  CT                  147               0.194±0.048                  0.614                        41              0.224±0.038   **0.014**   37   0.190±0.045   0.825   69    0.178±0.047   0.492
  TT                  69                0.189±0.042                  0.291                        17              0.217±0.036   **0.032**   17   0.019±0.045   0.757   35    0.173±0.036   0.847
  CT/TT               216               0.192±0.046                  0.422                        58              0.222±0.037   **0.042**   54   0.191±0.045   0.785   104   0.177±0.044   0.566
  rs6939861                                                                                                                                                                               
  GG                  122               0.192±0.048                                               30              0.227±0.045               34   0.189±0.048           58    0.174±0.040  
  AG                  136               0.198±0.052                  0.271                        41              0.234±0.052     0.536     31   0.190±0.038   0.930   64    0.179±0.047   0.536
  AA                  26                0.180±0.033                  0.258                        4               0.221±0.015     0.784     7    0.193±0.034   0.868   15    0.164±0.024   0.327
  AG/AA               162               0.195±0.050                  0.498                        45              0.233±0.050     0.589     38   0.191±0.037   0.892   79    0.176±0.044   0.788
  rs6941539                                                                                                                                                                               
  CC                  185               0.194±0.047                                               48              0.228±0.039               49   0.185±0.037           88    0.180±0.046  
  CT                  94                0.195±0.054                  0.887                        27              0.235±0.061     0.542     22   0.201±0.051   0.151   45    0.168±0.033   0.109
  TT                   5                0.163±0.021                  0.144                        NA                  NA           NA       1       0.195      0.785    4    0.155±0.013   0.284
  CT/TT               99                0.193±0.054                  0.908                        NA                  NA           NA       23   0.201±0.050   0.148   49    0.167±0.032   0.071

All tests used Student-T test. The results highlighted in bold show associations with expression levels of PGC protein in situ (P values \<0.05).

Discussion {#s4}
==========

This study highlights an important role of PGC genetic variations in the susceptibility to gastric cancer. We newly found associations between PGC rs3789210 CG/GG genotypes and reduced risk of gastric cancer and between PGC rs6939861 A variant allele and increased risks of both atrophic gastritis and gastric cancer. As for the haplotypes of PGC rs6941539-rs6912200-rs3789210-rs6939861 loci, TTCA and TTGG haplotypes were respectively associated with increased and reduced risks of both gastric cancer and atrophic gastritis and CTCA haplotype was associated with an increased risk of atrophic gastritis. Very interestingly, rs6912200 CT/TT genotypes had a positive interaction with *H. pylori* infection, synergistically elevated the risk of gastric cancer although this polymorphism had no main effect on disease risk. Moreover, healthy subjects who carried rs6912200 variant genotypes had lower histological and serum levels of PGC protein.

It is currently known that there are at least two different types of polymorphisms for PGC gene, including insertion/deletion and SNP. In 1993, Azuma et al initially reported that a 100 bp insertion/deletion within intron 7 of PGC gene was associated with an increased risk of gastric ulcer [@pone.0115955-Azuma1]. Subsequently, both Liu et al\'s and Sun et al\'s studies independently found its deletion allele was linked with an increased gastric cancer risk and lower histological levels of PGC protein [@pone.0115955-Liu1]--[@pone.0115955-Sun2]. As for the PGC SNP, in addition to PGC rs4711690, rs6458238 and rs9471643 identified previously [@pone.0115955-He1], our study newly found rs3789210 in intron 3 and rs6939861 in 3′ downstream of PGC gene had main effects on susceptibility to gastric cancer. So far, the rs6939861 polymorphism was the only SNP that was found to be associated with increased risks of gastric cancer and atrophic gastritis, with ORs ranging from 1.25 to 1.62. It is worth noting that the genotype frequencies distribution was deviated from Hardy-Weinberg equilibrium (HWE) in control subjects. There are two main possible interpretations accounting for this phenomenon, including the inappropriate selection of genotyping method or a lack of representativeness of selected population. Considering the case of the former interpretation, we found that the genotyping by Sequenom MassARRAY in this study showed a concordance of 100% of repeated detection for rs6939861. Additionally, the PCR-based sequencing in 5 random samples had validated the correction of genotyping for this SNP. Such quality control precludes the possibility of uncorrected genotyping of rs6939861 in this study. As for the control subjects in this study, they had two different sources. One part of the control subjects were recruited from the hospitals that underwent physical examination in Shenyang city and the other part of the control subjects were selected randomly from the participants in a health check program for gastric cancer screening in Zhuanghe County. It seems to be one possible interpretation for a deviation of rs6939861 from HWE in this study. Nevertheless, our findings for rs6939861 should be further validated in future study with a larger study sample size.

Apart from the host genetics, environmental factors also play a critical role in the development of gastric cancer. The effect of one confirmed risk environmental factor, *H. pylori* infection, has been concerned in this study. The present study observed that the PGC rs6912200 variant T allele had lower histological levels of PGC protein in gastric body tissues but it still did not exhibit any independent genetic effect on disease risk. Nevertheless, once infected by *H. pylori*, the subject carrying PGC rs6912200 variant genotypes has an increased risk of suffering from gastric cancer. In recent years, PGC protein has been considered as an important effector of *H. pylori* infection in stomach [@pone.0115955-DiMario1], [@pone.0115955-Nurgalieva1], [@pone.0115955-DiMario2]. Ning et al reported that the histological expression levels of PGC protein were prone to be affected by *H. pylori* [@pone.0115955-Ning1]. They found that histological PGC protein levels increased in acute *H. pylori* infection while declined in chronic *H. pylori* infection in accompany with the reduction of gland cells. *H. pylori* infection seems to play an essential role in the initiation of the genetic activity of PGC rs6912200 polymorphism. Our research group previously found another interaction effect between PGC rs4711690 polymorphism and *H. pylori* infection in the development of atrophic gastritis [@pone.0115955-He1]. Those evidences collectively suggest that PGC genetic variations may function as important effectors that respond to certain virulence factor of *H. pylori* and thereby affect the strength of host response to *H. pylori* infection. Previous studies also suggested that *H. pylori* could directly induce a series of pathophysiologic alterations in gastric epithelium or indirectly change the biological function or expression pattern of host gene via certain virulence factors, both of which advance the development of gastric cancer and its precursor, atrophic gastritis [@pone.0115955-Wen1], [@pone.0115955-He3]. However, the biological mechanism of interaction between PGC polymorphism and *H. pylori* infection during the process of gastric carcinogenesis is still unclear, which requires further molecular function studies to elucidate. It is worth mentioning that the resistance against *H. pylori* pathogenicity appears to be weakened among population who carry the rs6912200 variant genotypes. We should, therefore, take targeted prevention and elimination of *H. pylori* infection for those individuals seriously.

Influence of polymorphism on the gene expression at mRNA or protein level is one of the most common molecular mechanisms underlying the association between genotype and disease risk. Based on such a hypothesis, we explored to investigate whether the PGC polymorphisms are associated with PGC mRNA and protein expressions. We observed that rs6912200 in the 5′ upstream of PGC gene was related with the PGC protein level by both immunohistochemistry and ELISA detections. However, our results showed that the mRNA or protein results were not exactly accordant with the genetic association of rs3789210 and rs6939861. There are several possible explanations for this discordance. The sample used for expression experiments in this study is relatively small, which may underestimate the influence of polymorphism on gene expression. Also, we are wondering if there is other mechanism underlying this association that still could not be established by the present experiments. The fact that rs3789210 is located in intron region and the rs6939861 is located in 3′ downstream raised the possibility that there is a third factor such as non-coding RNA and splice factor involved in manipulating the function of PGC gene. Usually such factors display their gene modifying functions in specific conditions. So far we could not draw a definite conclusion on the molecular function for the associated polymorphisms.

We are aware that there are several major limitations in this study. First, the genotype-expression associations were not exactly accordant with the genotype-disease associations for the rs3789210 and rs6939861. This difference may be due to the limited sample size for the expression experiments. Also, there may be other mechanisms underlying these associations that still could not yet be established by mRNA or protein experiments. Second, in histological PGC protein experiments, we only enrolled the tissues extracted from healthy subjects other than from the cases with diseased stomaches (here referred to atrophic gastritis and gastric cancer patients). Our major considerations are as follows. Besides the host genetics, histological PGC expression could also be affected by several other factors such as status of gastric mucosa, location of affected or selected tissues, and state of *H. pylori* infection. Especially, the status of gastric mucosa and the location of tissue have significant effects on in situ PGC expression levels as described in previous studies [@pone.0115955-Ning1], [@pone.0115955-Li1]. Therefore, detection of histological PGC protein in cancerous tissues could not be accomplished in experimental practice. By contrast, the normal mucosa/mild superficial gastritis is an ascertained benign condition that has minimal impact by other confounding factors. Therefore, we considered the subjects with endoscopically- and histopathologically-confirmed normal stomach and slight superficial gastritis as eligible samples for PGC expression experiment in situ.

Taking together, this study found for the first time that PGC rs3789210 was associated with a reduced risk of atrophic gastritis and PGC rs6939861 was associated with increased risks of both atrophic gastritis and gastric cancer. There were joint effects of PGC rs6941539-rs6912200-rs3789210-rs6939861 loci, demonstrating genetic roles of TTCA, TTGG and CTCA haplotypes in altering susceptibility to atrophic gastritis and/or gastric cancer. Moreover, PGC rs6912200 CT/TT genotypes had a positive interaction with *H. pylori* infection in conferring an increased risk of gastric cancer, and individuals carrying such genotypes had lower levels of histological and serum PGC protein expression. Our findings indicate a further research direction for PGC genetic variation in gastric carcinogenesis, and also provide an important clue for personalized *H. pylori* management in the overall strategy to reduce the high prevalence of gastric cancer.
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###### 

**The location of the studied 4 SNPs.** All the SNPs within PGC gene and its extended 5000 bp upstream and downstream regions identified in the HapMap project in Chinese Han Beijing population (Release 27,Phase I+II+III). This figure showed a visual appearancemanifestation for the location of the studied 4 SNPs which was a supplement for the Supplementary [table 1](#pone-0115955-t001){ref-type="table"}. The tagSNP rs6939861 located in promoter region of PGC gene, rs3789210 located in intron 6, and rs6941539 and rs6912200 located in 3′ untranslated region of PGC gene.

(TIF)

###### 

Click here for additional data file.

###### 

**Original color image and converted gray image.** Positive expression of PGC protein in the cytoplasm of gastric gland cells (immunohistochemical staining ×400). Original color image was converted to a gray scale image before measuring integrated optical density and area of interest of all the positive PGC staining in each gray scale image. (A and B) Original color image and gray scale image in gastric body; (C and D): Original color image and gray scale image in gastric angulus; and (E and F): Original color image and gray scale image in gastric antrum.

(TIF)

###### 

Click here for additional data file.

###### 

**TagSNPs for PGC gene according to genotype data of HapMap project in Chinese Han Beijing population.**

(DOCX)

###### 

Click here for additional data file.
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